Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of RPH-001 vs Avastin in Healthy Male Volunteers
NCT03131700Phase 1Withdrawn
- Sponsor
- TRPharm
- Start
- Dec 2017
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of RPH-001 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by TRPharm. Primary endpoints: Maximum plasma concentration, Area under concentration-time curve from time zero to the last sampling time and 1 more. Planned start Dec 2017; status: withdrawn.
02
Drugs
RPH-001
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03131700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131700.